Evidence map›Paper›PMID 32963999›Full record

ArticleERJ open research2020

Response to mepolizumab treatment is sustained across 4-weekly dosing periods.

Ian D Pavord, Eugene R Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H Bel, Peter Howarth, Daniel J Bratton, Frank C Albers, Steven Yancey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Monoclonal Antibodies and Airway Diseases.International journal of molecular sciences · 2020
    Review
  2. Difficult and Severe Asthma in Children.Children (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

Ian D PavordRespiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
Eugene R BleeckerGenomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Roland BuhlDept of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.
Pascal ChanezClinique des bronches allergies et sommeil, INSERM C2VN Center and CIC Nord APHM, Aix-Marseille University, Marseille, France.
Elisabeth H BelDept of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Peter HowarthGlobal Medical Franchise, GSK, Brentford, UK.
Daniel J BrattonClinical Statistics, GSK, Stockley Park, UK.
Frank C AlbersRespiratory Medical Franchise, GSK, Research Triangle Park, NC, USA.
Steven YanceyRespiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
Research Triangle Park Foundation · USFrimley Park Hospital · GBInserm · FRJohannes Gutenberg University Mainz · DEUniversity of Amsterdam · NLUniversity of Arizona · USUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMepolizumab (100 mg delivered

methodsThis was a

findingseDiary data and the proportion of patients experiencing ≥1 exacerbation were similar during the first and second 2 weeks of a dosing period across all mepolizumab doses.

interpretationThese results demonstrate that the response to mepolizumab is sustained over the 4-weekly dosing period with no differences across a 10-fold dose range and supports the use of the current mepolizumab dosing regimen in patients with severe eosinophilic asthma.

Identifiers

PMID32963999
PMCPMC7487353
OpenAlexW3086113824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.